RecruitingNot ApplicableNCT05146297

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Diversity and Inclusion in Research Underpinning Trials


Sponsor

Icahn School of Medicine at Mount Sinai

Enrollment

644 participants

Start Date

Apr 23, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This proposal brings together multidisciplinary teams from four New York City institutions charged with reducing cancer disparities that affect approximately two million people residing in some of the most diverse and underserved communities in the United States. The intent of this collaborative research is captured by its acronym, DISRUPT: Diversity \& IncluSion in Research Underpinning Prevention \& Therapy Trials. To disrupt the norms that maintain heightened risk and poorer outcomes experienced by BIPOC, the research team propose three integrated and synergistic aims to improve diversity and inclusion in CTs through disruptive approaches at the community (Aim 1), provider, system and patient (Aim 2), and basic and translational scientist levels (Aim 3). All three aims focus on metrics for changing norms reified in institutional policies and established practice that will provide essential evidence to translate and scale these changes to institutions and networks involved in cancer treatment research. In Aim 1, the research team will partner with local organizations to formulate and disseminate new norms regarding cancer care and research and diffuse these new norms throughout the community via community organizations and Health Ambassadors bringing a different vantage point on CTs, raising awareness and increasing demand for access to cancer research. In Aim 2, the research team will create an electronic approach to identify key clinical characteristics of patients and trials and match patients and trials and bring these data to patients and their physicians at the time of key decisions. In Aim 3, the research team will provide and integrate essential experiential training in diversity, social determinants of health and the importance of conducting community-relevant work into basic and translational science training. This DISRUPT proposal provides the foundation to disrupt norms about cancer clinical trials in our communities, delivery systems and scientific research enterprises.


Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This study is focused on improving diversity and inclusion in cancer research. Researchers are enrolling patients with breast, lung, or liver cancer who are facing a treatment decision to better understand how different patient groups participate in clinical trials and to develop strategies to include more underrepresented communities in cancer prevention and treatment research. **You may be eligible if...** - You are over 21 years old and have been diagnosed with invasive breast, lung, or liver cancer - You are currently facing a treatment decision - You can give consent and communicate in English or Spanish - Your oncologist or care provider is participating in the study **You may NOT be eligible if...** - You are not able to give informed consent - You do not speak English or Spanish - You do not have invasive breast or liver cancer - You are not currently facing an imminent treatment decision Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALClinical trial match-list

Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.

BEHAVIORALMatch-list intervention

Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.


Locations(3)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Herbert Irving Comprehensive Cancer Care Center

New York, New York, United States

Albert Einstein College of Medicine

The Bronx, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05146297


Related Trials